ConductScience.org, home
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
API referenceFor AI assistants

Trial · NCT02585778

Adverse events112

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 112

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
otherNasopharyngitisInfections and infestationsAlirocumab 75 mg Q2W/Up to 150 mg Q2W17344
otherNasopharyngitisInfections and infestationsPlacebo Q2W9170
seriousEosinophiliaBlood and lymphatic system disordersAlirocumab 75 mg Q2W/Up to 150 mg Q2W1344
seriousEosinophiliaBlood and lymphatic system disordersPlacebo Q2W0170
seriousLymphadenopathyBlood and lymphatic system disordersAlirocumab 75 mg Q2W/Up to 150 mg Q2W0344
seriousLymphadenopathyBlood and lymphatic system disordersPlacebo Q2W1170
seriousAcute myocardial infarctionCardiac disordersAlirocumab 75 mg Q2W/Up to 150 mg Q2W0344
seriousAcute myocardial infarctionCardiac disordersPlacebo Q2W1170
seriousAngina pectorisCardiac disordersAlirocumab 75 mg Q2W/Up to 150 mg Q2W1344
seriousAngina pectorisCardiac disordersPlacebo Q2W0170
seriousAngina unstableCardiac disordersAlirocumab 75 mg Q2W/Up to 150 mg Q2W1344
seriousAngina unstableCardiac disordersPlacebo Q2W1170
seriousAortic valve stenosisCardiac disordersAlirocumab 75 mg Q2W/Up to 150 mg Q2W0344
seriousAortic valve stenosisCardiac disordersPlacebo Q2W1170
seriousCardiac failureCardiac disordersAlirocumab 75 mg Q2W/Up to 150 mg Q2W1344
seriousCardiac failureCardiac disordersPlacebo Q2W0170
seriousCoronary artery diseaseCardiac disordersAlirocumab 75 mg Q2W/Up to 150 mg Q2W1344
seriousCoronary artery diseaseCardiac disordersPlacebo Q2W0170
seriousCoronary artery occlusionCardiac disordersAlirocumab 75 mg Q2W/Up to 150 mg Q2W1344
seriousCoronary artery occlusionCardiac disordersPlacebo Q2W0170

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02585778/events

API referenceFor AI assistants